Partnerships of many kinds — from outsourcing to licensing agreements to consultancies — help companies navigate this increasingly global business environment. ... Dan Stanton Editor at Bioprocess International and Managing Editor at Xconomy. BioProcess International US West. These interviews were conducted at the 2018 BioProcess International European Summit in Amsterdam, The Netherlands. There are 200+ professionals named "Dan Stanton", who use LinkedIn to exchange information, ideas, and opportunities. Formerly editor of Biopharma-Reporter and in-Pharmatechnologist, Dan has particular expertise in biotech, bioprocessing methods and equipment, drug delivery, Even as it matures, the biopharmaceutical industry is still a highly entrepreneurial one. From Repligen, to Lonza, to Pfenex, Patrick Lucy has had an illustrious career. Following a year that saw Pfizer bring to the US and Europe the first vaccine against COVID-19, the firm has raised its production targets for 2021 from 1.3 billion doses to 2 billion doses, and expects to deliver 200 million doses to the US by end of May. The BPI EU TV program was a combined effort of BioProcess International magazine and KNect365 Life Sciences, both of which are business units within Informa's Knowledge & Networking division. Dan Stanton Verified Journalist ... Editor - BioProcess Insider, part of Informa Life Sciences' BioProcess International. In this podcast,…, Repligen and Navigo have launched an affinity resin specifically for the purification of COVID-19 vaccines. Dan Stanton Editor at Bioprocess International and Managing Editor at Xconomy. Created and edited by veteran journalist Dan Stanton, every edition of BioProcess Insider provides expert and insider perspective on: “Gene therapy is an…, The addition of a plant in Liverpool, UK, from AbbVie will support ambitions in the biologics and cell and gene therapy space, says service firm Pharmaron. AbbVie acquired ABL as part of its $63 billion acquisition of Allergan in 2019. The contract development and manufacturing organization (CDMO) has entered a lease agreement, adding a facility in Rockville, Maryland with supporting infrastructure, including HVAC and flooring and Water for injection (WFI) system in place The additional manufacturing space will complement Vigene’s nearby GMP manufacturing plant, acquired in 2016 through the purchase of assets from Omnia Biologics. Vice President Sales/Project Manager. by Dan Stanton The plant in Bloomington received a Form 483 with five observations in May, but Catalent says a second US FDA inspection shows issues have been resolved. But they are not alone, and New Hampshire-based firm Avitide recently finalized its…, Newly formed CDMO Resilience takes over the once-troubled Allston facility in Massachusetts from Sanofi, retaining all 250 staff. Leveraging commentary from vaccine industry experts and analyzing the range of emerging vaccine modalities, Stanton surveys how industry responses to the COVID-19 pandemic are fostering…, The proposed acquisition of Cognate BioServices will bring services firm Charles River Laboratories autologous and allogeneic cell therapy, plasmid DNA and viral vector manufacturing capabilities. The BioProcess International event is in Boston September 9-12, ... Zhiping Yao, Director for Process Science at JOINN Biologics US, spoke with BioProcess Insider’s Dan Stanton ahead of her talk in the "Speed from Gene to Market" session at BPI Boston in September. Created and edited by veteran journalist Dan Stanton, every edition of BioProcess Insider provides expert and insider perspective on: Breaking financial movements and M&A activity Her presentation focuses on carrying out developability assessments to progress therapeutic antibodies into and through the clinic. View Dan Stanton’s profile on LinkedIn, the world’s largest professional community. BioProcess Insider delivers the latest news and expert views impacting the research, development, and manufacturing of biologics directly to your inbox. While the handful of COVID-19 vaccines approved so far are not protein-based…, Pfizer says it is relatively simple to rejig the formulation and manufacturing infrastructure for its approved mRNA vaccine in the case of COVID-19 variants. Bioprocessing begins upstream, most often with culturing of animal or microbial cells in a range of vessel types (such as bags or stirred tanks) using different controlled feeding, aerating, and process strategies. In September 2016, German biomanufacturer Boehringer Ingelheim partnered with Austrian based ViraTherapeutics GmbH to develop an oncolytic virus therapy platform and bring various programs through the clinic. The SARS-CoV-2 novel coronavirus has galvanized what was a stagnant and oligopoly-run vaccine industry. See the complete profile on LinkedIn and discover Dan… Dan has 2 jobs listed on their profile. View Dan Stanton’s profile on LinkedIn, the world’s largest professional community. Chinese pharma services firm Pharmaron Beijing Co is set to pay $118.7 million in cash to AbbVie for its Allergan Biologics Limited (ABL) business, located in Liverpool, UK. by Dan Stanton Black and minority workers are consistently overlooked in the biomanufacturing industry due to unconscious – or perhaps conscious – racism, LucasPye Bio CEO Tia Lyles-Williams explains in The BioProcess Insider Expression System podcast. Many technologies are used to characterize biological products, manufacturing processes, and raw materials. Drug products combine active pharmaceutical ingredients with excipients in a final formulation for delivery to patients in liquid or lyophilized (freeze-dried) packaged forms — with the latter requiring reconstitution in the clinical setting. Last November, ‘National Resilience’ – less formerly known as Resilience – raised over $800 million in funding and launched itself as a contract development and manufacturing organization (CDMO). As with fellow bioprocess vendors (Danaher, Sartorius, Thermo Fisher etc), COVID-19 played a major part in Repligen’s 2020 top line, with its…, Having its own plasmid DNA capabilities will launch Catalent into areas like mRNA and non-viral gene delivery, the CDMO says. View Dan Stanton’s profile on LinkedIn, the world’s largest professional community. Zhiping Yao, director of process science at JOINN Biologics, speaks to Bioprocess Insider’s Dan Stanton ahead of her talk within the "Speed from Gene to Market" track at BPI Boston in September. View Dan Stanton’s profile on LinkedIn, the world’s largest professional community. While Emergent has its own product line (contributing $340 million in the quarter, with its smallpox vaccine…, The SARS-CoV-2 novel coronavirus has galvanized what was a stagnant and oligopoly-run vaccine industry. BioProcess International Theater (29) Interactive Sessions (28) Global Innovation Hubs (22) Interactive Special Programs (11) ... CEO Steve Burton talks to Bioprocess Insider editor Dan Stanton about… BioProcess International Theater. Dan has 3 jobs listed on their profile. Emerging Techniques, Technologies and Strategies. ©2021 BioProcess International All Rights reserved, COVID-19 Therapeutic Development & Production, eBook: Vaccines — COVID-19 Invigorates a Stagnant Industry, Charles River to reenter CDMO space in $875m Cognate buy, Affinity resins: Avitide gears up to support COVID-19 vaccine makers, Resilience bags Sanofi-Genzyme plant in Boston, Vigene upping viral vector capacity by 50% through Maryland facility, Rentschler catapults into the cell and gene therapy space through UK investment. Life sciences pulled in $10.6 billion of this, up 52% on 2019. Montpellier Area, France. Contract development and manufacturing organization (CDMO) Avid Bioservices had been looking to build out the Myford, Tustin, California production facility for several years to prepare for continued high demand from the biologics sector. For the full year 2020, Danaher Corporation reported net sales of $22.3 billion, a 24.5% increase on the previous year. Stay at the Forefront of COVID-19 Therapeutic Development & Production. Dan Spacie Chief Executive Officer. BioProcess International . Previous. While Danaher does not detail its individual business financial figures, the contributions from Cytiva – acquired for $21 billion last April –  and Pall Biotech…. Vaccine Industry Reinvigorated by COVID-19 - BioProcess International By Dan Stanton , John Godshalk bioprocessintl.com — The SARS-CoV-2 novel coronavirus has galvanized what was a stagnant and oligopoly-run vaccine industry. At the time, the firm said it will provide “new, better, faster ways” to manufacture cell and gene therapies and alluded to having capacity at multiple facilities to carry out this mission. Bioprocess service and consumable firms are looking to support the next wave of COVID-19 vaccines as they progress through the clinic. A survey of around 1,100 senior executives across 20 countries commissioned by bioprocess vendor Cytiva has highlighted industry’s confidence in the biopharma space. The number of options and applications is growing every day — with quality by design (QbD) giving impetus to this expansion. See the complete profile on LinkedIn and discover Dan… Beginning with harvest of material from a bioreactor, downstream processing removes or reduces contaminants to acceptable levels through several steps that typically include centrifugation, filtration, and/or chromatographic technologies. Last year, bioprocess technology firm Repligen teamed with protein engineering firm Navigo Proteins GmbH to develop an affinity ligand specifically for COVID-19 vaccines. BioProcess Insider delivers the latest news and expert views impacting the research, development, and manufacturing of biologics directly to your inbox. Journalist covering the international biopharmaceutical manufacturing and processing industries. Editor Dan Stanton takes a look beyond the nuts and… “The addressable market for Cognate’s CDMO services principally cell therapy and plasmid production…, Avitide says a specific SARS-CoV-2 virus spike protein affinity resin greatly helps the current COVID-19 efforts and could greatly accelerate the speed of response in future pandemics. Meet the speakers. Dan Stanton EDITOR, BIOPROCESS INSIDER Speaking In [Available On-Demand] Having inhouse manufacturing capabilities gives cell and gene therapy developers a competitive advantage. ... Dan Stanton placeholder image. Like many COVID-19 vaccine and therapeutic efforts themselves, the collaboration plus speed of development have borne fruit with the firms launching the NGL COVID-19 Spike Protein Affinity Resin this week. Dan has 2 jobs listed on their profile. Since it began working on a COVID-19…, Merck & Co. will add a pipeline of precision immune modulators and a drug design and discovery platform through the proposed acquisition of Pandion. The planned 175,000 square-foot plant – set to create 90 jobs once operational – will support Biogen’s gene therapy pipeline across multiple therapeutic areas. Drug products combine active pharmaceutical ingredients with excipients in a final formulation for delivery to patients in liquid or lyophilized (freeze-dried) packaged forms — with the latter requiring reconstitution in the clinical setting. With respondents scoring several sectors within the industry, the Biopharma Resilience Index averaged an overall score of 6.6 out of 10. Dan Stanton is editor and founder of BioProcess Insider, an online publication focused on reporting the latest business news and opinion across the biomanufacturing space, and part of the BioProcess International brand. As cell and gene ... BioProcess International Theater. Many technologies are used to characterize biological products, manufacturing processes, and raw materials. For the fourth quarter 2020, the firm reported sales of $200 million – up from nothing the previous year – as regulatory approvals began rolling in for its messenger RNA (mRNA) COVID-19 vaccine mRNA-1273. The fourth quarter itself pulled in $108 million, representing a 56% increase on the same period 2019. Dan Stanton Editor at Bioprocess International and Managing Editor at Xconomy. See the complete profile on LinkedIn and discover Dan… Gareth John Macdonald GEN: July 1, 2020: Repligen boosting single-use portfolio with Engineered Molding Technology buy. by Dan Stanton Lonza says observations made by the FDA at its Texas facility should not further hamper the already delayed approval of Bristol-Myers Squibb’s lymphoma CAR-T candidate liso-cel. Montpellier Area, France. Beginning with harvest of material from a bioreactor, downstream processing removes or reduces contaminants to acceptable levels through several steps that typically include centrifugation, filtration, and/or chromatographic technologies. Repligen and Navigo target next-wave COVID vaccines with affinity resin, Pfizer cites ‘simplicity’ of mRNA production to overcome COVID-19 variants, Bioprocessing ‘running hot’ for Danaher with $1.3bn COVID windfall to come, Industry calls for standardization and simplification to boost manufacturing agility, BMS ups Breyanzi production with Massachusetts cell therapy plant, Stem Cell Derived Exosome Production in Stirred-Tank Bioreactors, Bluebird Bio investigating potential vector role in AML and MDS cases, Eurofins on how to get faster sterility results, Gilead Sciences partner with Gritstone for potential HIV cure, Workforce, tax incentives and US access attract more biotechs to Puerto Rico, Biogen acknowledges risk on manufacturing provisions for aducanumab. Dan Stanton Editor at Bioprocess International and Managing Editor at Xconomy Région de Montpellier, France + de 500 relations Created and edited by veteran journalist Dan Stanton, every edition of BioProcess Insider provides expert and insider perspective on: What a year it has been for Moderna Therapeutics. Partnerships of many kinds — from outsourcing to licensing agreements to consultancies — help companies navigate this increasingly global business environment. Beginning with harvest of material from a bioreactor, downstream processing removes or reduces contaminants to acceptable levels through several steps that typically include centrifugation, filtration, and/or chromatographic technologies. This site is part of the Informa Connect ... BioProcess Insider Inquiries. View Dan Stanton’s profile on LinkedIn, the world’s largest professional community. View Dan Stanton’s professional profile on LinkedIn. The future of ® 2018 ? Emerging … Family-owned contract development and manufacturing organization (CDMO) Rentschler offers mammalian manufacturing and fill and finish services for biologics but has now expanded into cell and gene therapy production through a deal with the CGT Catapult, based in Stevenage, UK. View Dan Stanton’s profile on LinkedIn, the world’s largest professional community. View Dan Stanton’s profile on LinkedIn, the world's largest professional community. Podcast: Industry veteran moves to Lykan Bioscience, and this time its personal! Even as it matures, the biopharmaceutical industry is still a highly entrepreneurial one. Dan has 8 jobs listed on their profile. Having In-House Manufacturing Capabilities Gives Cell and Gene Therapy Developers a Competitive Advantage — Discuss. In this inaugural BioProcess Insider eBook, the first of four to be published in 2021, founding editor Dan Stanton explores economic and technical conditions that until now have hampered innovation in vaccine development and discouraged market entry for emerging biotechnology companies. The US Food and Drug Administration (FDA) recently published a Form 483 it issued to Catalent’s biomanufacturing facility in Bloomington, Indiana following an inspection in April and May this year. ©2021 BioProcess International All Rights reserved, COVID-19 Therapeutic Development & Production, Biogen to build $200m NC plant to support gene therapy ambitions, Pharmaron to buy Allergan Biologics biz from AbbVie for $119m, Avid kicks off second phase of $60-70m capacity expansion, Industry calls for standardization and simplification to boost manufacturing agility, Moderna investing $400m in mRNA capacity for COVID-19 and beyond, Merck buying Pandion Therapeutics in $1.85bn deal, Repligen eyes more M&A and expansions as demand continues to rocket, Catalent commits to pDNA, buying Delphi and expanding a Maryland plant, Emergent CDMO biz ‘thriving’ in COVID-19 environment, eBook: Vaccines — COVID-19 Invigorates a Stagnant Industry, BMS ups Breyanzi production with Massachusetts cell therapy plant, Stem Cell Derived Exosome Production in Stirred-Tank Bioreactors, Bluebird Bio investigating potential vector role in AML and MDS cases, Resilience bags Sanofi-Genzyme plant in Boston, Eurofins on how to get faster sterility results, Gilead Sciences partner with Gritstone for potential HIV cure, Pfizer cites ‘simplicity’ of mRNA production to overcome COVID-19 variants, Workforce, tax incentives and US access attract more biotechs to Puerto Rico. See the complete profile on LinkedIn and discover Dan… View the profiles of professionals named "Dan Stanton" on LinkedIn. This event is brought to you by the organizers of the BioProcess International Conference & Exhibition Series. Plans for a $30-40 million expansion finally materialized last July, but no date or details were…, Executives from Novavax, Fujifilm, and Biocon have called for standardized processes and simplified regulations after a Cytiva-led survey showed improving manufacturing agility is a major priority for biopharma. Dan Stanton Last week, we reported that Repligen and Navigo launched an affinity resin specifically for the purification of COVID-19 vaccines. 29 - 31 Mar 2021. by Dan Stanton Boehringer Ingelheim has acquired ViraTherapeutics for €210 million ($245 million) and tells us how it will integrate the viral therapy firm into its oncology business. View Dan Stanton’s profile on LinkedIn, the world’s largest professional community. Dan has 10 jobs listed on their profile. 8 BioProcess International 16(5)e3 May 2018 E-Book continue to feature predominantly in biopharmaceutical pipelines. The deal, announced today, will see Merck & Co. pay $60 per share in cash for the Cambridge, Massachusetts-based firm, totalling roughly $1.85 billion. Bioprocessing begins upstream, most often with culturing of animal or microbial cells in a range of vessel types (such as bags or stirred tanks) using different controlled feeding, aerating, and process strategies. His latest career move is to Lykan Bioscience, a Massachusetts-based contract Manufacturing Services Organization (MSO) and provider of end-to-end solution for cell-based therapies, where he took on the role of chief operating officer (COO) in January. “With this new facility, Biogen is investing in robust and scalable gene therapy manufacturing with the goal of ensuring reliable supply to patients worldwide,” the company said in a statement. Interviews conducted for BPI EU TV in Vienna, Austria in 2019 Leveraging commentary from vaccine industry experts and analyzing the range of emerging vaccine modalities, Stanton surveys how industry responses to the COVID-19 pandemic are fostering…. BPI Staff BioProcess International: February 24, 2020: Repligen up on OPUS® and Gene Therapy Demand. The number of options and applications is growing every day — with quality by design (QbD) giving impetus to this expansion. by Dan Stanton Thermo Fisher’s CDMO business Patheon will add 16,000 L of single-use capacity through a US$50 million (€41 million) expansion at its St Louis facility. Pandion is developing therapies for the tissue-specific treatment of patients with autoimmune and inflammatory diseases and organ transplants. The BioProcess International event series provides you access to the science, technologies and contacts you need to accelerate promising biologics towards commercial success. The fourth quarter 2020 produced record revenues for Emergent BioSolutions, with the firm reporting sales of $583 million, up 62% on the year prior. In this inaugural BioProcess Insider eBook, the first of four to be published in 2021, founding editor Dan Stanton explores economic and technical conditions that until now have hampered innovation in vaccine development and discouraged market entry for emerging biotechnology companies. Now the…, CDMO Vigene Biosciences has leased a 52,000 square foot facility in Maryland to support ongoing demand for viral vectors. BioPhorum. In this inaugural BioProcess Insider eBook, the first of four to be published in 2021, founding editor Dan Stanton explores economic and technical conditions that until now have hampered innovation in vaccine development and discouraged market entry for emerging biotechnology companies. From business publication BioProcess International comes The BioProcess Insider Expression Platform (BIEP). Rentschler will establish its manufacturing capabilities – including adeno-associated virus (AAV) vector production – through “a significant…, In the latest episode of the BioProcess Insider Expression Platform, we explore the evolution of cell and gene therapy production with new COO of Lykan Bioscience, Patrick Lucy. Its lead candidate, bispecific antibody PT101, is in early-phase clinical trial for ulcerative colitis…, Repligen says it will both reinvest in its manufacturing network and look for M&A opportunities to feed the high demand for bioprocess consumables. Chair: Dan Stanton, BioProcess Insider Panelist: Magnus Schroeder, PhD, VP Process Development, Avid Bioservices Panelist: Daniel Slone, VP & Head of Downstream Manufacturing, Samsung Biologics. For the full year 2020, bioprocessing tech firm Repligen Corporation reported sales of $366 million, up 36% year-on-year. Dan Stanton. Dan Stanton. But according to Hannah Freegard, senior editor at…, Moderna aims to up capacity for its COVID-19 vaccine to 1.4 billion doses through investment in ‘flexible’ manufacturing, which it says will offset any risk from variants or future overcapacity. For the full year, sales tallied $1.56 billion, up 41% on 2019. The deal, financial details of which have not been divulged, will also bring Catalent a 17,000 square-foot facility in Gosselies, Belgium,…, The COVID-19 pandemic has highlighted the growing mammalian and viral vaccines market and placed Emergent in a “leading position” in the CDMO space, says CEO Bob Kramer. The agreement announced yesterday will see Charles River pay $875 million in cash for the contract development and manufacturing organization (CDMO). See the complete profile on LinkedIn and discover Dan… to). See the complete profile on LinkedIn and discover Dan… Dan has 2 jobs listed on their profile. The proposed sale – expected to go through in the second quarter…, After beginning a $15 million expansion of its Myford, California facility late last year, CDMO Avid Bioservices is starting work on a second extension estimated to cost $45 to $55 million. Through the deal, Charles River has propelled itself into the manufacturing space, entering a lucrative cell therapy and plasmid production market. “Because of the dire need to vaccinate more…, Danaher Corporation reports double-digit sales growth at its bioprocess units Pall and Cytiva, inflated by COVID-related dividends it says will continue this year. The lease brings Vigene’s total lab…, German CDMO Rentschler will set up manufacturing capabilities at the UK’s Cell and Gene Therapy (CGT) Catapult, launching itself into the regenerative medicine space. Catalent has entered into an agreement to buy fellow contract development and manufacturing organization (CDMO) Delphi Genetics, adding – if the deal goes through – a plasmid DNA (pDNA) platform and supporting production services from preclinical to Phase III. Dan has 1 job listed on their profile. Montpellier Area, France. Dan Stanton BioProcess International: September 1, 2020: Continuous Processing: A Step on the Way to Bioprocess 4.0. Dan has 6 jobs listed on their profile. Biogen has laid down plans to build a gene therapy manufacturing at its Research Triangle Park (RTP) manufacturing campus in North Carolina. BioProcess Insider delivers the latest news and expert views impacting the research, development, and manufacturing of biologics directly to your inbox.